Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the ...

Hims & Hers Health ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the ...

One of the most widely watched names in the healthcare sector is Hims & Hers Health Inc. (NYSE: HIMS), not only due to its ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

According to Benzinga Pro, Hims & Hers Health's peer group average for short interest as a percentage of float is 8.31%, which means the company has more short interest than most of its peers. Did you ...

Shares of Hims Hers Health Inc (NYSE:HIMS) fell more than 3% early Tuesday before paring losses to around 0.2% in afternoon trade, after rising legal risks and a data disclosure drove swings in ...

Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs. These drugs are ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...